IPO11

Across TCGA pan-cancer cohorts, IPO11 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated IPO11 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IPO11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IPO11 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, UCEC, and TGCT are the cancer types where IPO11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.071	0.544	<.001	18	view →
UCEC	DFS	Median	II,III,IV	0.915	0.438	.033	8	view →
TGCT	DFS	Median	All	0.174	0.801	.041	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	OS	Median	III,IV	1.000	0.382	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

IPO11–LIHC (DFS)

Open the LIHC breakdown →